---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-24-001899"
form_type: "8-K"
ticker: null
cik: "0001708331"
company_name: "Virpax Pharmaceuticals, Inc."
filed_at: "2024-11-29T23:59:59+00:00"
generated_at: "2026-05-29T12:57:52.201268+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Virpax Pharmaceuticals reduces shareholder meeting quorum threshold to 34%

## Summary
- Amendment adopted November 27, 2024, lowering quorum from a majority to 34% of voting power.
- Change applies to all future shareholder meetings; filed as Exhibit 3.1.
- Bylaw modification may ease passage of shareholder proposals and director elections.

## SEC filing metadata
- accession: 0001731122-24-001899
- form_type: 8-K
- cik: 0001708331
- company_name: Virpax Pharmaceuticals, Inc.
- filed_at: 2024-11-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708331/000173112224001899/0001731122-24-001899-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708331/000173112224001899/e6175_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-24-001899
- JSON: https://secwatch.observer/filing/0001731122-24-001899.json
- Plain text: https://secwatch.observer/filing/0001731122-24-001899.txt

## Key facts
- Governance Changes
  Virpax Pharmaceuticals, Inc.: Reduced the quorum requirement for shareholder meetings from a majority of voting power to 34% of voting power (effective 2024-11-27).
  - Change: bylaw amendment
  - Effective: 2024-11-27
  source text: On November 27, 2024, Virpax Pharmaceuticals, Inc. (the “Company”) amended its Amended and Restated Bylaws (the “Bylaws”) to modify the quorum requirement for shareholder meetings. The amendment reduced the quorum threshold from a majority of the voting power of the Company’s outstanding shares entitled to vote at a meeting to 34% of such voting power.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708331/000173112224001899/0001731122-24-001899-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.